<DOC>
	<DOCNO>NCT01545947</DOCNO>
	<brief_summary>The main purpose first study combine investigational dual mTOR inhibitor , CC-223 , agent ( erlotinib investigational agent , oral azacitidine ) establish maximum tolerated dose level combination order evaluate effect future clinical trial advance non-small cell lung cancer .</brief_summary>
	<brief_title>Study Assessing Safety , Pharmacokinetics Efficacy CC-223 With Either Erlotinib Oral Azacitidine Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Men woman , 18 year old , histologically cytologicallyconfirmed , Stage IIIB/IV NonSmall Cell Lung Cancer ( NSCLC ) tumor progression follow least one prior treatment regimen [ ( either chemotherapy Epidermal Growth Factor Receptor inhibitor ( EGFR ) ] advanced disease . There restriction number prior treatment regimen allow . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 1 . 3 . Adequate organ function . 4 . Adequate contraception ( appropriate ) . 5 . Consent retrieve archival tumor tissue . 6 . Consent repeat tumor biopsy ( dose expansion phase ) . 1 . Prior systemic cancerdirected treatment investigational drug within 4 week 5 half life , whichever short except erlotinib may continue intervention subject allocate Arm A . 2 . Symptomatic central nervous system metastasis . 3 . Acute chronic pancreatitis . 4 . Persistent diarrhea malabsorption &gt; Grade 2 , despite medical management . 5 . Impaired cardiac function significant cardiac disease . 6 . Diabetes active treatment , fast blood glucose &gt; 126 mg/dL , ( glycated haemoglobin ) HbA1c &gt; 6.5 % . 7 . Known Human Immunodeficiency Virus ( HIV ) , chronic hepatitis B C infection . 8 . Prior treatment investigational dual target ripamycin 1 ( TORC1 ) / target ripamycin 2 ( TORC2 ) , Phosphatidylinositol 3Kinase ( PI3K ) , protein kinase B ( Akt ) inhibitor . Prior treatment analog rapamycin ( rapalogs ) allow . 9 . Major surgery &lt; 2 week prior start study drug . No specific wash require radiotherapy . Subjects must recover effect recent therapy might confound safety evaluation study drug . 10 . Pregnant breastfeeding , inadequate contraception . 11 . History concurrent second malignancy require ongoing systemic treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Cancer Lung</keyword>
	<keyword>Stage IIIB Non-Small Cell Lung Cancer</keyword>
	<keyword>IV Non-Small Cell Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>